Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
International Journal of Molecular Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1107-3756 Online ISSN: 1791-244X
Journal Cover
March-2015 Volume 35 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
March-2015 Volume 35 Issue 3

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

X chromosome inactivation in human parthenogenetic embryonic stem cells following prolonged passaging

  • Authors:
    • Quan Qi
    • Chenhui Ding
    • Pingping Hong
    • Gang Yang
    • Yanxin Xie
    • Jing Wang
    • Sunxing Huang
    • Ke He
    • Canquan Zhou
  • View Affiliations

    Affiliations: Reproductive Medical Center, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510080, P.R. China
  • Published online on: December 18, 2014     https://doi.org/10.3892/ijmm.2014.2044
  • Pages: 569-578
  • Copyright: © Qi et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

The present study aimed to investigate the X chromosome inactivation (XCI) status in long-term cultured human parthenogenetic embryonic stem cells. One human embryonic stem (hES) cell line and 2 human parthenogenetic embryonic stem (hPES) cell lines were subjected to long-term culture in vitro (>50 passages). Karyotyping, array-based comparative genomic hybridization (aCGH), X-inactive specific transcript (XIST) RNA, immunofluorescence staining and real-time PCR were used to assess the chromosome karyotypes of these cells and the XCI status. X chromosome microdeletion was observed in the hPES-2 cells following culture for 50 passages. As early as 20 passages, XIST RNA expression was detected in the hPES-2 cells and was followed by low X-linked gene expression. The XIST RNA expression level was higher in the differentiated hPES-2 cells. The hPES-2' cells that were subclones of hPES-2 retained the XCI status, and had low XIST and X-linked gene expression. XIST RNA expression remained at a low level in the differentiated hPES-2' cells. The human biparental embryonic stem (hBES)-1 and hPES-1 cells did not exhibit XCI, and the differentiated hPES-1 cells had high expression levels of XIST RNA. In conclusion, the chromosome karyotypes of some hPES cell lines revealed instabilities. Similar to the hES cells, the hPES cells exhibited 3 XCI statuses. The unstable XCI status of the hPES-2 line may have been related to chromosome instability. These unstable chromosomes renedered these cells susceptible to environmental conditions and freezing processes, which may be the result of environmental adaptations.

Introduction

Human embryonic stem (hES) cells have been widely used in regenerative medicine due to their capacity to differentiate into various cell types both in vitro and in vivo (1,2). However, transplant rejection and the unstable epigenetic state of hES cells from human embryos limit their use in research and therapy. Human parthenogenetic embryonic stem (hPES) cells, the genetic materials of which are derived entirely from a single oocyte, are considered to be a possible means to resolve the issue of immune rejection (3), and several hPES cell lines have been generated (4–8). These stem cell lines have exhibited infinite proliferation, self-renewal and differentiation properties, similar to embryonic stem cell lines in vitro.

The completely undifferentiated status and the original genetic characteristics of hES cells are important for clinical and research trials (9). It has been previously reported that the evolution and selection of hES cell clones cultured in vitro causes genetic and epigenetic changes, which alters the behavior and fate of these hES cells (10–13). The genetic and epigenetic stabilities of hES cells are crucial for their use in regenerative medicine. Epigenetic changes include DNA methylation, histone modifications, genomic imprinting and X chromosome inactivation (XCI).

XCI involves one of the X chromosomes in cells of a female mammal and is crucial for embryo formation and cell biology (14). To date, hES cells have been shown to have 3 different XCI statuses. With status I in the hES cells, both X chromosomes are activated in the undifferentiated stage, and XCI occurs randomly following differentiation, which is close to what occurs in mouse embryonic stem cells (15–17). With status II, XCI has already occurred in undifferentiated hES cells, and approximately 20–70% of hES cells can be found with X-inactive specific transcript (XIST) clouds accumulated on a specific chromosome (11,18). Finally, with status III, XCI has occurred without XIST RNA expression (11). Certain studies have demonstrated that the hES cell XCI states are related to the culture conditions used and spontaneous differentiation potential (19). However, the XCI statuses of hPES cell lines have not been thoroughly investigated to date.

Thus, in the present study, we assessed the statuses of hPES cell lines following prolonged passaging in culture in vitro. We focused on the XCI status of hPES cell lines (hPES-1 and hPES-2) under long-term culture conditions (>50 passages) in vitro. We found that hPES cells also had 3 XCI statuses, although different XCI statuses could be found within the same cell line. These differences in XCI status in hPES cells may be related to their X chromosome instability. Furthermore, low expression levels of X-linked genes were detected in the hPES cells that were related to their XIST RNA expression levels. The XCI status is related to the genetic characteristics or strains of embryonic stem cells that are cultured in vitro and the freezing conditions used. Our findings suggest that it is essential to assess the XCI status of hES cells and to consider this as one of the indicators used for evaluating the quality of hES cells.

Materials and methods

Ethics statement

Our protocols were approved by the Ethics Committee of the First Affiliated Hospital of Sun Yat-Sen University. Donors voluntarily donated experimental materials with no financial compensation and written informed consent was obtained.

Derivation and culture of hES, human foreskin fibroblasts (HFFs) and human endometrial stromal cells (hESCs)

Three hES lines were analyzed in this study, including human biparental embryonic stem cell line-1 [hBES-1, passage (P)12], hPES cell line-1 (hPES-1, P10) and hPES cell line-2 (hPES-2, P10). The hBES-1 cells were from a cHES1 cell line that was derived and propagated in our embryonic stem cell laboratory, as previously described (20). The hPES-1 and hPES-2 cells were from hPES1 and hPES2 cell lines that were also derived and propagated in our laboratory, as previously described (6). Culture, cryopreservation and warming methods for undifferentiated hESCs and embryoid body (EB) formation were as previously described, and the origins and detailed characterizations of the pluripotency of these cell lines were verified (6,20,21). The derivation and culture of hESCs and HFFs were as previously described (22,23).

Spontaneous hESC differentiation was induced as previously described (6,20). hPES-1 and hPES-2 cells at P60 and hPES-2′ cells at P70 were removed from the dishes using 1 mg/ml of collagenase IV (cat. no. 17104-019; Invitrogen/Gibco, Grand Island, NY, USA) and cultured under suspension conditions. Spontaneous EBs were grown in medium that included 80% Knockout-DMEM (Cat. no. 10829-018), supplemented with 20% serum replacement, 0.1 mM 2-mercaptoethanal and 1% non-essential amino acids (Cat. no. 11140-050) (all from Invitrogen/Gibco). After 14 days, all differentiated samples from EBs were collected.

Karyotyping

The hBES-1 (P19) colonies, hESCs and HFFs were incubated with 0.2 μg/ml of colchicine (Invitrogen/Gibco) at 37°C for 3 h. The cells were collected, trypsinized, washed with phosphate-buffered saline (PBS) (Cat. no. 10010-049; Invitrogen/Gibco) and then incubated with 0.075 M potassium chloride at 37°C for 10 min. These cells were fixed with methanol:glacial acetic acid (1:3) 3 times and then dropped onto glass slides. Chromosome spreads were Giemsa-banded and photographed. Karyotypes were assessed using normal G-banding procedures and 50 metaphase II spreads were examined for each sample. A normal karyotype showed normal chromosome numbers and G-banding patterns in the spreads examined.

Array-based comparative genomic hybridization (aCGH)

The hBES-1 (P42), hPES-1 (P70), hPES-2 (P20) and hPES-2 (P55) cell colonies were lysed, after which genomic DNA was amplified using a SurePlex DNA Amplification system (BlueGnome Ltd., Cambridge, UK), according to the manufacturer’s instructions. Whole genome amplification (WGA) products were processed as previously described (24) according to the BlueGnome protocol (available at: http://www.cytochip.com/). Briefly, WGA products were fluorescently labeled and competitively hybridized to 24sure V3/24sure + arrays with matched control SureRef reference DNA (male/female) (both from BlueGnome Ltd.) in an array CGH experiment format. A laser scanner, InnoScanw 710 AL (Innopsys, Carbonne, France), was used to excite the hybridized fluorophores of a Fluorescent Labelling system (BlueGnome Ltd.), and used to read and store the resulting hybridization images. The scanned images were then analyzed and quantified using algorithm fixed settings with BlueFuse Multi software (BlueGnome Ltd.), a software package that automatically performed the steps of grid placement, quantification, normalization and post-processing.

Flow cytometry for hESC phenotyping

The hBES-1 (P70) and hPES-2 (P70) cell colonies were digested with 0.25% Trypsin-EDTA (Cat. no. 15400-054; Invitrogen/Gibco) to prepare single cells. The hESCs (1−2×106) were suspended in 0.5 ml of Dulbecco’s phosphate-buffered saline (DPBS; Cat. no. 14190-144; Invitrogen/Gibco). Subsequenlty, 2–3 ml of 70% ethanol were added to each tube, mixed and incubated at 4°C for 30 min. Cell suspensions were washed, centrifuged and resuspended in 400 μl of DPBS. Cell suspensions were filtered, 1 mg/ml of propidium iodide (Asegene, Guangdong, China) was added followed by incubation for 30 min. Cell suspensions were analyzed using a FACSCalibur Flow Cytometer with CellQuest software (Becton-Dickinson, Bergen County, NJ, USA).

DNA fluorescence in situ hybridization (FISH)

For DNA FISH analysis, the hBES-1, hPES-1 and hPES-2 cells were dropped onto wet slides and dried at room temperature overnight. They were then fixed with 0.1% Tween-20 and 0.01 N HCl and dehydrated with an ethanol series at concentrations of 70, 85 and 100%. CEPX/CEPY (Cytocell, Banbury, Oxfordshire, UK) was used for hybridization for 2 h. Finally, the cells were stained with 4′,6-diamidino-2-phenylindole (DAPI; Cytocell) for 5 min. The cells were examined under a fluorescence microscope (Leica DMIRE 2; Leica Microsystems GmbH, Wetzlar, Germany). At least 20 cells were examined for each experiment.

RNA FISH

The hESCs, hBES-1 (P20 and P40), hPES-1 (P20 and P40), hPES-2 (P20 and P40) and hPES-2′ (P70) cells were used for RNA FISH analysis. XIST RNA-FISH (Biosearch Technologies, Novato, CA, USA) was carried out according to the protocol provided by Stellaris FISH Probes (Biosearch Technologies; https://www.biosearchtech.com/display.aspx?catid=224%2c318), as previously described (15). The XIST probe sequences are listed in Table I. hES cell colonies and hESCs were cultured on Millicell EZ slides (Cat. no. PEZGS0496; Millipore, Billerica, MA, USA). Stained colonies were examined under a fluorescence microscope (Leica DMIRE 2; Leica Microsystems GmbH).

Table I

XIST probe sequences.

Table I

XIST probe sequences.

Probe sequence (5′→3′)Probe sequence name
gaattgcagcgctttaagaactgaaggHuman XIST-RNAFISHprobe_1
gagagagtaagaaatatggctgcagcaHuman XIST-RNAFISHprobe_2
gacgtgtcaagaagacactaggagaaa HumanXIST-RNAFISHprobe_3
gaagggaatcagcaggtatccgataccHuman XIST-RNAFISHprobe_4
gatattccagagagtgcaacaacccacHuman XIST-RNAFISHprobe_5
cttagcttaactgcagagtcattctctHuman XIST-RNAFISHprobe_6
ccgagttatgcggcaagtctaaaatggHuman XIST-RNAFISHprobe_7
tgcctgacctgctatcatccatcttgcHuman XIST-RNAFISHprobe_8
ttagctcatgcaatgcacatgacttccHuman XIST-RNAFISHprobe_9
cgatacaacaatcacgcaaagctcctaHuman XIST-RNAFISHprobe_10
ccgcaatgtcaaaatcgccattttaagHuman XIST-RNAFISHprobe_11
cattttggacaacctaacaaagcacagHuman XIST-RNAFISHprobe_12
acttgaacactgcgacagaactggatcHuman XIST-RNAFISHprobe_13
catcttttcctgtgtgaccgcacatgtHuman XIST-RNAFISHprobe_14
catgttttacactgcggcaagaccttcHuman XIST-RNAFISHprobe_15
catatgacaacgcctgccatattgtccHuman XIST-RNAFISHprobe_16
gatgtccacgtgacaaaagccatgataHuman XIST-RNAFISHprobe_17
ctctaattggctgtgatcaattccaccHuman XIST-RNAFISHprobe_18
gtgtgtcatcagtctaattccatcttcHuman XIST-RNAFISHprobe_19
gtgttcctcttgaggaaggcaggaattHuman XIST-RNAFISHprobe_20
tcagtactgaagatcagcaatgccaagHuman XIST-RNAFISHprobe_21
cagagtgctgtctaatccaatgggtagHuman XIST-RNAFISHprobe_22
cgactggtagtcttcatgattaatgggHuman XIST-RNAFISHprobe_23
ctctaagaatgagtcagtcccactgctHuman XIST-RNAFISHprobe_24
aaggtggtaggtagttcacactatctaHuman XIST-RNAFISHprobe_25
aaggaaacttgggtagtcagaactcagHuman XIST-RNAFISHprobe_26
attgtagcgtgcaaataggatacagagHuman XIST-RNAFISHprobe_27
ctagtacagaggtcttgagtagtaaggHuman XIST-RNAFISHprobe_28
cactgctgaacactagggaagtgagtgHuman XIST-RNAFISHprobe_29
ctagtgcaaaggtcttgactagaggtc HumanXIST-RNAFISHprobe_30
tagcactcctgctgctttgccaaggagHuman XIST-RNAFISHprobe_31
gcagtataagagaagaagcactagctaHuman XIST-RNAFISHprobe_32
agcgggattctactctaacataggggcHuman XIST-RNAFISHprobe_33
caagagagtgaattcaggctagttagaHuman XIST-RNAFISHprobe_34
tacttccagctgggatgtaaatacagtHuman XIST-RNAFISHprobe_35
caattacatgccatctacagttcgaagHuman XIST-RNAFISHprobe_36
gataggtcagaaacccaagtctaattgHuman XIST-RNAFISHprobe_37
ggccttaggtgtcaccaaccatgctgtHuman XIST-RNAFISHprobe_38
ctagtgcatagcaacctcgacaaatacHuman XIST-RNAFISHprobe_39
cagtgtgcgattacgcacataaatgtcHuman XIST-RNAFISHprobe_40
gagagtaggaccttattcacatggaatHuman XIST-RNAFISHprobe_41

[i] XIST, X-inactive specific transcript.

Immunofluorescence staining

The hESCSs, hBES-1 (P20 and P40), hPES-1 (P20 and P40), hPES-2 (P20 and P40), and hPES-2′ (P70) cells were used for immunofluorescence staining. The hES cell colonies and hESCs were cultured on Millicell EZ slides (Millipore) and fixed with 4% paraformaldehyde (Cat. no. P6148) for 20–30 min, treated with 0.5% Triton X-100 (Cat. no. X100) for 20 min and then blocked with 10% goat serum (Cat. no. G9023) (all from Sigma, St. Louis, MO, USA) for 1 h. The cells were then incubated with primary antibodies at 4°C overnight. The primary antibodies included mouse anti-histone H3 trimethyl K27 (H3K27me3; 1:100; Cat. no. ab6147) and rabbit anti-histone H3 acetyl K9 (H3K9ac; 1:200; Cat. no. ab61231) (both from Abcam, Cambridge, UK). The cells were then rinsed 3 times with PBS and incubated at 37°C for 60 min with goat anti-mouse IgM R-PE (1:200; Cat. no. 488800A; Invitrogen, Carlsbad, CA, USA) or goat anti-rabbit IgG FITC (1:200; Cat. no. A24532; Invitrogen), and finally stained with DAPI for 5 min. The stained colonies were examined under a fluorescence microscope (Leica DMIRE 2; Leica Microsystems GmbH).

Real-time polymerase chain reaction (PCR)

XIST expression (probe XIST ID: Hs01079824_m1; Ambion, Austin, TX, USA) was assessed in the hESCs and HFFs, the hBES-1, hPES-1 and hPES-2 cells at P20, P40 and P60, the hPES-2′ undifferentiated cells at P50, P60 and P70, as well as in EBs of hPES-1 (P60), hPES-2 (P60) and hPES-2′ (P70) cells. X-linked gene expression was assessed in the hBES-1, hPES-1 and hPES-2 cells at P20, P40 and P60, and in the hPES-2′ undifferentiated cells at P50, P60 and P70. Real-time PCR was carried out using TaqMan gene expression Cells-to CT kits (Cat. no. 4399002; Ambion) as described in the TaqMan gene expression Cells-to CT kit protocol (http://www.lifetechnologies.com/order/catalog/product/4399002?ICID=search-product). The target X-linked genes were alpha thalassemia/mental retardation, X-Linked (ATRX; assay ID: Hs00230877_m1) and cysteine-rich hydrophobic domain 1 (CHIC1; assay ID: Hs01371424_m1) (both from Ambion). Relative XIST gene and other X-linked gene expression levels were calculated using the 2−∆∆CT method following normalization to GAPDH (assay ID: Hs02758991_m1; Ambion) expression levels.

Pluripotent characterizations of hPES-2 cells

To exclude the possibility that XIST expression in undifferentiated hPES-2 cells occurred due to their differentiation in culture, we assessed the pluripotent characterizations of the hPES2 cells. EBs were used to assess the differentiation capability of the hPES-2 cells in vitro using specific immunofluorescence staining.

Alkaline phosphatase (AP) activity was assessed by histochemical staining. The hPES-2 cell colonies on a mouse embryonic fibroblast (MEF) feeder layer were fixed with 4% paraformaldehyde for 20–30 min, treated with 0.5% Triton X-100 for 10 min and then stained with BCIP/NBT (Beyotime, Haimen, Jiangsu, China) for 5–13 min prior to examination.

Briefly, for immunofluorescence staining, the hPES-2 cell colonies were incubated with the following primary antibodies against stage-specific embryonic antigens: rat anti-human stage-specific embryonic antigen (SSEA)3 monoclonal antibody (Cat. no. LV1528429), rat anti-human SSEA4 monoclonal antibody (Cat. no. LV1488380), mouse anti-human tumor-rejection antigen (TRA)-1-60 monoclonal antibody (Cat. no. LV1541028), mouse anti-human TRA-1-81 monoclonal antibody (Cat. no. LV1580855); mouse anti-human octamer-binding transcription factor 4 (OCT-4) monoclonal antibody (Cat. no. MAB4419A4) and mouse anti-human Nanog homeobox (NANOG) monoclonal antibody (Cat. no. MABD24A4) (all from Millipore) (all were used at 1:100). The secondary antibodies were as follows: goat anti-rat IgM 488 (Cat. no. 549138), goat anti-mouse IgM R-PE (Cat. no. 488800A) (both from Invitrogen), goat anti-rat IgG, FITC (Cat. no. CW0167) and goat anti-mouse IgG, FITC (Cat. no. CW0113) (both from CWBIO, Beijing, China) (all were used at 1:200).

Gene expression levels in the pluripotent hPES2 cells were assessed by real-time PCR. The primers used for OCT-4, REX1 [also referred to as zinc-finger protein-42 (ZFP42)], SRY (sex determining region Y)-box 2 (SOX2), NANOG, Lin-28 homolog A (LIN28) and nucleophosmin (NPM1) are listed in Table II. β-actin was used as a control. PCR products were size-fractionated by 1% agarose gel electrophoresis and were visualized by ethidium bromide staining. Final analysis was made using an image analyzer (Bio-Rad, Hercules, CA, USA).

Table II

Primers for pluripotency genes.

Table II

Primers for pluripotency genes.

GeneForward
(5′-3′)
Reverse
(5′-3′)
Annealing temperature (°C)Product size (bp)
OCT-4 GACAACAATGAGAACCTTCAGGAGA TTCTGGCGCCGGTTACAGAACCA55218
NANOG CAGAAGGCCTCAGCACCTAC CTGTTCCAGGCCTGATTGTT55216
REX-1 GCGTACGCAAATTAAAGTCCAGA CAGCATCCTAAACAGCTCGCAGAAT58306
SOX-2 CCCCCGGCGGCAATAGCA TCGGCGCCGGGGAGATACAT58448
LIN28 AGTAAGCTGCACATGGAAGG ATTGTGGCTCAATTCTGTGC58420
NPM1 TGGTGCAAAGGATGAGTTGC GTCATCATCTTCATCAGCAGC58343
β-actin CGGATGTCCACGTCACACTT GTTGCTATCCAGGCTGTGGT55469

[i] OCT-4, octamer-binding transcription factor 4; NANOG, Nanog homeobox; REX-1 [also referred to as zinc-finger protein-42 (Zfp42)]; SOX-2, SRY (sex determining region Y)-box 2; LIN28, Lin-28 homolog A; NPM1, nucleophosmin.

Statistical analysis

The results from real-time PCR for the expression levels of the different genes in the different cell lines were compared by ANOVA. Pearson correlation coeffi-cients were determined to assess possible associations between XIST RNA and X-linked gene expression levels. A P-value of <0.05 was considered to indicate a statistically significant difference.

Results

Karyotype instability in hPES cell lines

The hBES-1, hPES-1 and hPES-2 are hES cell lines that have been strictly validated. The hBES-1 cell line is the parent source of hES cell lines, and hPES-1 and hPES-2 cells are well known parthenogenetic embryonic stem cell lines (6,20). The hBES-1, hPES-1 and hPES-2 cells had stabilized at >70 generations when cultured under identical culture conditions. The hBES-1, hPES-1 and hPES-2 cells retained the unique morphological and growth characteristics of hESCs (Fig. 1A and B).

Figure 1

Human embryonic stem (hES) cell line morphologies and karyotypes. (A) Morphologies of human biparental embryonic stem cell line-1 (hBES-1), human parthenogenetic embryonic stem cell line-1 (hPES-1) and hPES-2 cell colonies at passage (P)20 and P70 as observed under an inverted microscope. (B) Morphologies of hPES-2′ cell colonies at P50 and P70 as observed under an inverted microscope. (C) Karyotypes. Endometrial stromal cells (ESCs) at P2 (positive control): normal 46,XX; human foreskin fibroblasts (HFFs) at P5 (negative control): normal 46,XY; and hBES-1 cells at P19: normal 46,XX. (D) Array-based comparative genomic hybridization (aCGH). hBES-1 cells (P42): normal 46,XX; hPES-1 cells (P70): normal 46,XX; hPES-2 cells (P20): normal 46,XX; and hPES-2 cells (P55): X microdeletion [XX,del(X)(q22.3;q28),+(17)(q121.31;q25.3)]. (E) hBES-1 and hPES-2 cell DNA contents as assessed by FACS; all were diploid.

We found that the chromosome karyotypes of hPES-2 cells changed during their long-term culture in vitro. At P20 (early generations), the results from aCGH for the hPES-2 cells were 46,XX. At P55, X chromosome microdeletions were observed in the hPES-2 cells, and the aCGH results were 46,XX,del(x) (q22.3;q28),+(17)(q121.31;q25.3) (Fig. 1C–E). In our previous study [Mai et al (6)], we reported X chromosome microdeletions in the same hPES cell lines. These phenomena indicated that the hPES-2 cell chromosomes were unstable and that their karyotypes could change during long-term culture. These phenomena did not occur in the hBES-1 and hPES-1 cell lines (Table III).

Table III

Karyotypes of human embryonic stem cells.

Table III

Karyotypes of human embryonic stem cells.

Chromosome karyotypingaCGHFACS
hBES-146,XX (P19)46,XX (P42)Diploid (P70)
hPES-146,XX (P40) [6[46,XX (P70)N/A
hPES-2 46,XX,del(X)(q22;q24), del(1)(q21;q25) (P57) [6[46,XX (P20)
46,XX,del(X)(q22.3;q28),+(17)(q121.31;q25.3) (P55)
Diploid (P70)

[i] hBES-1, human biparental embryonic stem cell line-1; hPES-1, human parthenogenetic embryonic stem cell line-1; aCGH, Array-based comparative genomic hybridization; N/A, no available data.

Three XCI statuses identified in hPES cells

XIST RNA and H3K27me3 accumulation on X chromosomes has been reported to be a sign of XCI, accompanied by the loss of H3K9ac expression at H3K27me3 accumulation sites (25–31). In this study, we used XIST RNA, H3K27me3 and H3K9ac as indicators of XCI.

We assessed the XCI status of hBES-1, hPES-1 and hPES-2 cell clones at P20 and P40, and found that XIST RNA and H3K27me3 did not accumulate in the hBES-1 and hPES-1 cells, which suggested that early-passage hBES-1 and hPES-1 cells did not undergo XCI. Subsequently, we further verified the X chromosome contents in the hBES-1, hPES-1 and hPES-2 cells using CEPX/CEPY FISH. These 3 hES cell lines all contained 2 X chromosomes (Fig. 2A). However, XIST RNA and H3K27me3 accumulation and H3K9ac loss were observed in the hPES-2 cells at P20, which suggested that XCI had been activated during early passage and maintained in the hPES-2 cells at P40 (Fig. 2B and C, Table IV). A previous study suggested that XCI in mouse embryonic stem cells indicated cell differentiation (32). However, in this study, the hPES-2 cells still expressed high levels of pluripotency genes and proteins and formed EBs in vitro, which suggested that the hPES-2 cells did not undergo differentiation (Fig. 3). Real-time PCR results also showed that XIST RNA expression was high in hPES-2 cells, but was very low or negative in hBES-1 and hPES-1cells (P<0.001) (Fig. 4A).

Figure 2

X chromosome inactivation (XCI) statuses of human biparental embryonic stem (hBES) and human parthenogenetic embryonic stem (hPES) cell lines. (A) CEPX/CEPY FISH analysis for hBES-1, hPES-1 and hPES-2 cells: red and green spots indicate chromosomes Y and X, respectively. All these human ES cells had 2 X chromosomes with no Y chromosome (white arrow). (B) X-inactive specific transcript (XIST) RNA FISH: endometrial stromal cells (ESCs) and hPES-2 cells: XIST RNA FISH signal (orange color and white arrow) showed XIST RNA coating on Xi; human foreskin fibroblasts (HFFs), hBES-1, hPES-1 and hPES-2′ cells: no XIST RNA FISH signals. (C) H3K9ac/H3K27me3 immunofluorescence. hPES-2 cells: immunostaining results with antibodies against H3K27me3 (red color and white arrow) coated on Xi without H3K9ac (green color) coat. hBES-1, hPES-1 and hPES-2′ cells: no H3K27me3 signals were detected in the cells. Punctate XIST FISH signals and foci of H3K27me3 without H3K9ac staining indicated the presence of Xi.

Figure 3

Pluripotentiality of human parthenogenetic embryonic stem cell line-2 (hPES-2). (A) Alkaline phosphatase (AP) staining, (B) embryoid bodies (EBs), (C) pluripotency gene expression, including octamer-binding transcription factor 4 (OCT-4), REX1 [also referred to as zinc-finger protein-42 (Zfp42)], SRY (sex determining region Y)-box 2 (SOX2), Nanog homeobox (NANOG), Lin-28 homolog A (LIN28) and nucleophosmin (β-actin was used as a control), amplified by real-time PCR, and (D) pluripotency immunofluorescent markers, including stage-specific embryonic antigen (SSEA)3, SSEA4, tumor-rejection antigen (TRA)-1-60, TRA-1-81, OCT-4 and NANOG.

Figure 4

Gene expression. (A) Average X-inactive specific transcript (XIST) RNA expression levels in human biparental embryonic stem (hBES) and human parthenogenetic embryonic stem (hPES) cell lines. The average XIST RNA expression was higher in the hPES-2 cells (P<0.001, n=3). (B) Relative XIST RNA expression levels in hPES-1 [passage (P)60], hPES-2 (P60), and hPES-2′ (P70) cells and their embryoid bodies (EBs). Relative XIST RNA expression in EBs of hPES-1 and hPES-2 cells was >5-fold higher compared to the EBs of hPES-2′ cells [normalization to endometrial stromal cells (ESCs)]. (C) Average relative expression levels of alpha thalassemia/mental retardation, X-Linked (ATRX) and cysteine-rich hydrophobic domain 1 (CHIC1_in hBES and hPES cells. Average relative expression levels of ATRX and CHIC1 in hBES-1 and hPES-1 cellls was >2-fold higher than that in hPES-2 cells (n=3, normalization to hPES-2 cells). (D) Relative expression levels of ATRX and CHIC1 in hPES-2 and hPES-2′ cells. Relative expression levels of ATRX and CHIC1 in hPES-2′ cells at P60 were >2-fold higher than that in hPES-2′ cells at P70 of which were similar to hPES-2 cells at P60 (normalization to hPES-2 cells at P60). Statistical comparisons were made by one-way ANOVA. *P<0.05 indicates significant difference.

Table IV

XIST RNA and H3K27me3 statuses of hES cell lines.

Table IV

XIST RNA and H3K27me3 statuses of hES cell lines.

XIST RNA
H3K27me3
P20P40P20P40
hBES-1−−−−
hPES-1−−−−
hPES-2++++

P70P70

hPES-2′−−

[i] XIST, X-inactive specific transcript; hES, human embryonic stem; hBES-1, human biparental embryonic stem cell line-1; hPES-1, human parthenogenetic embryonic stem cell line-1.

To validate the XCI status in the hPES-2 cells, hPES-2 cells at P45 (subclones of hPES-2 cells; designated as hPES-2′ cells) that had been stored in liquid nitrogen were recovered. These cells grew normally and passed to P70. However, these cells differed from the hPES-2 cells, as the XIST RNA expression levels in the hPES-2′ cells were very low (P<0.001; Fig. 4A); XIST RNA and H3K27me3 did not accumulate on X chromosomes (Fig. 2B and C, Table IV). In EB forming assays, the hPES-1 and hPES-2 EBs had a higher XIST RNA expression, whereas the hPES-2′ EB XIST RNA expression was extremely low (Fig. 4B).

All of these results indicated that there were different XCI statuses in the hPES cells: i) pre-XCI status: hPES-1 cells that did not express XIST RNA, and re-expressed XIST RNA following differentiation; ii) XCI status: hPES-2 cells expressed XIST RNA and this expression was sustained following differentiation; and iii) quiescent XCI status: low XIST RNA expression in hPES-2′ cells, which remained low following differentiation.

X-linked gene expression levels in hPES cells

ATRX and CHIC1 are X-linked genes that are silenced during XCI. As expected, the ATRX and CHIC1 expression levels were very low in the hPES-2 cells, and higher in the hBES-1 and hPES-1 cells. The ATRX and CHIC1 expression levels in the hPES-2′ cells at P60 were higher than those in the hPES-2 cells at P60, but were decreased in the hPES-2′ cells at P70 and were as low as in those in the hPES-2 cells at P60, suggesting that a low XIST RNA expression in the hPES-2′ cells at P70 had occurred (Fig. 4C–D).

The results from a correlation analysis suggested that there was a tendency for a negative correlation between X-linked genes and XIST RNA expression levels, although this was not statistically significant (P>0.05; n=3). An increased sample size may have provided a significant result. However, this still indicated that XIST RNA mediated the silencing of these X-linked genes (Fig. 5).

Figure 5

A tendency for a negative correlation between X-linked gene and X-inactive specific transcript (XIST) RNA expression levels, but no statistically significant difference was observed in the human parthenogenetic embryonic stem cell line-2 (hPES-2). (A) alpha thalassemia/mental retardation, X-Linked (ATRX) and XIST expression: R2=−0.91, P=0.268, n=3; (B) CHIC1 and XIST expressions: R2=−0.81, P=0.402, n=3.

Discussion

Using hPES cells may be a means to resolve human embryo stem cell transplantation immune rejection issues (33,34), although the security of their application remains a concern. Studies have found that human and murine parthenogenetic embryonic stem cells have genetic instabilities and epigenetic abnormalities (33,35). Thus, it is essential to understand the genetic and epigenetic characteristics of hPES.

In the current study, we found that some hPES cell lines had chromosome karyotype instabilities. The hPES-1 cells had a stable karyotype following serial passage, whereas the hPES-2 cells lost some X chromosome fragments after 50 passages. Previous studies have demonstrated that parthenogenetic embryonic stem cells often undergo changes associated with karyotype abnormalities (33). Liu el al (36) also reported X chromosome losses in hPES cells. These, as previously suggested, the genetic characteristics of hPES cells would not be stable following long-term culture (37).

To date, 3 XCI statuses have been reported for hES cells. With status I in hES cells, 2 X chromosomes are both activated in the undifferentiated stage, and XCI occurs randomly following differentiation, similar to what occurs in mouse embryonic stem cells (15–17). With status II, XCI has already occurred in undifferentiated hES cells, and approximately 20–70% of hES cells will have XIST clouds accumulated on specific chromosomes (11,18). With status III, XCI has occurred without XIST RNA expression (11). The XCI status may be associated with the genetic characteristics of the cells themselves, although it may also be affected by the culture conditions used. Some investigators have assumed that XCI in hES cells moved from state I to a transition state II to III, as an adaptation to the environmental conditions in vitro (11,18). Lengner et al (19) found that blastocyst-derived hES cells did not have XCI when cultured under low oxygen concentrations (5%); this status was associated with the pluripotency of stem cells and was affected by the oxygen concentration and atmospheric pressure. These data indicate that the culture conditions used, the methods used to establish cell lines, as well as other factors affect the XCI status of hES cells.

In the present study, we also found 3 XCI statuses that respectively matched those of hES cells: i) pre-XCI status, which was similar to hES status I: hPES-1 cells did not express XIST RNA, but did express X-linked genes, and re-expressed XIST RNA following differentiation, hPES-1 cells for example; ii) XCI status, which was similar to hES status II: hPES-2 cells expressed XIST RNA and expressed X-linked genes at a very low level, and XIST RNA expression was sustained following differentiation, hPES-2 cells for example; and iii) quiescent XCI status, which was similar to hES status III: low XIST RNA and X-linked gene expression in hPES-2′ cells, and XIST RNA expression remained at a low level following differentiation, hPES-2′ cells for example. The results observed for the hPES-2′ cells may have been due to their development from hPES-2.

The hES cells used in this study all underwent freezing and thawing and long-term culture in vitro. A previous study suggested that the freezing process and the in vitro culture conditions may alter the epigenetic state of stem cells (19). In this study, unstable XCI was found in the hPES-2 cells, and stable XCI (XCI I) was found in the hPES-1 and hBES-1 cells, which was similar to the results from the study by Liu et al (38). Unstable XCI may have been associated with chromosome instability in the hPES-2 cells. Unstable chromosomes rendered this cell line susceptible to environmental conditions and the freezing process used, which may have been the result of a environmental adaptations.

There is no paternal genetic material in parthenogenetic embryonic stem cells, and the 2 X chromosomes are all from the mother. The XCI status of hPES cells that lack paternal genetic material seems to be similar to that of embryonic stem cells. Liu et al (36) found that early-passage hPES cells did not exhibit XCI, but that XIST RNA expression and the XCI status emerged slowly during the course of long-term culture in vitro. Others have found that different hPES cells lines have different XCI states, which was similar to the situation with hES cells (38). To the best of our understanding, the XCI status of hES cells and the factors that affect it are more significant.

In conclusion, our data demonstrated that the chromosome karyotypes of some hPES cell lines exhibited instabilities. Similar to the hES cells, the hPES cells had 3 XCI statuses. Unstable XCI of hPES-2 cells may be related to chromosome instability. Unstable chromosomes render this cell line susceptible to environmental conditions and the freezing process used, which may be the result of an environmental adaptation. XCI plays important roles in sustaining embryo formation and cell biological activity (14), and an abnormal XCI can result in some diseases (39). Thus, it is essential to routinely assess the XCI status of hES cells, including hPES cells prior to their use in clinical applications.

Acknowledgments

We are very grateful to Professor Mai Qingyun and Professor Li Tao for their assitance in the derivation and characterization of the hBES-1, hPES-1 and hPES-2 cell lines. This study was supported in part by grants from the National Natural Science Foundation of China (81270750); the National 973 program (2012CB947604); Guangdong Provincial Key Laboratory of Reproductive Medicine (2012A06140003).

References

1 

Lindvall O and Kokaia Z: Stem cells for the treatment of neurological disorders. Nature. 441:1094–1096. 2006. View Article : Google Scholar : PubMed/NCBI

2 

Vats A, Bielby RC, Tolley NS, Nerem R and Polak JM: Stem cells. Lancet. 366:592–602. 2005. View Article : Google Scholar : PubMed/NCBI

3 

Szabó P and Mann JR: Expression and methylation of imprinted genes during in vitro differentiation of mouse parthenogenetic and androgenetic embryonic stem cell lines. Development. 120:1651–1660. 1994.PubMed/NCBI

4 

Lin G, OuYang Q, Zhou X, et al: A highly homozygous and parthenogenetic human embryonic stem cell line derived from a one-pronuclear oocyte following in vitro fertilization procedure. Cell Res. 17:999–1007. 2007. View Article : Google Scholar : PubMed/NCBI

5 

Revazova ES1, Turovets NA, Kochetkova OD, Kindarova LB, Kuzmichev LN, Janus JD and Pryzhkova MV: Patient-specific stem cell lines derived from human parthenogenetic blastocysts. Cloning and Stem Cells. 9:432–449. 2007. View Article : Google Scholar : PubMed/NCBI

6 

Mai Q, Yu Y, Li T, et al: Derivation of human embryonic stem cell lines from parthenogenetic blastocysts. Cell Res. 17:1008–1019. 2007. View Article : Google Scholar : PubMed/NCBI

7 

Revazova ES, Turovets NA, Kochetkova OD, et al: HLA homozygous stem cell lines derived from human parthenogenetic blastocysts. Cloning Stem Cells. 10:11–24. 2008. View Article : Google Scholar

8 

Lu Z, Zhu W, Yu Y, et al: Derivation and long-term culture of human parthenogenetic embryonic stem cells using human foreskin feeders. J Assist Reprod Genet. 27:285–291. 2010. View Article : Google Scholar : PubMed/NCBI

9 

Zhao Q, Wang J, Zhang Y, Kou Z, Liu S and Gao S: Generation of histocompatible androgenetic embryonic stem cells using spermatogenic cells. Stem Cells. 28:229–239. 2010.

10 

Maitra A, Arking DE, Shivapurkar N, et al: Genomic alterations in cultured human embryonic stem cells. Nat Genet. 37:1099–1103. 2005. View Article : Google Scholar : PubMed/NCBI

11 

Silva SS, Rowntree RK, Mekhoubad S and Lee JT: X-chromosome inactivation and epigenetic fluidity in human embryonic stem cells. Proc Nat Acad Sci USA. 105:4820–4825. 2008. View Article : Google Scholar : PubMed/NCBI

12 

Allegrucci C, Thurston A, Lucas E and Young L: Epigenetics and the germline. Reproduction. 129:137–149. 2005. View Article : Google Scholar : PubMed/NCBI

13 

Allegrucci C, Denning C, Priddle H and Young L: Stem-cell consequences of embryo epigenetic defects. Lancet. 364:206–208. 2004. View Article : Google Scholar : PubMed/NCBI

14 

Tomkins DJ, McDonald HL, Farrell SA and Brown CJ: Lack of expression of XIST from a small ring X chromosome containing the XIST locus in a girl with short stature, facial dysmorphism and developmental delay. Eur J Hum Genet. 10:44–51. 2002. View Article : Google Scholar : PubMed/NCBI

15 

Sugawara O, Takagi N and Sasaki M: Correlation between X-chromosome inactivation and cell differentiation in female preimplantation mouse embryos. Cytogenet Cell Genet. 39:210–219. 1985. View Article : Google Scholar : PubMed/NCBI

16 

Hall LL, Byron M, Butler J, et al: X-inactivation reveals epigenetic anomalies in most hESC but identifies sublines that initiate as expected. J Cell Physiol. 216:445–452. 2008. View Article : Google Scholar : PubMed/NCBI

17 

Dhara SK and Benvenisty N: Gene trap as a tool for genome annotation and analysis of X chromosome inactivation in human embryonic stem cells. Nucleic Acids Res. 32:3995–4002. 2004. View Article : Google Scholar : PubMed/NCBI

18 

Shen Y, Matsuno Y, Fouse SD, et al: X-inactivation in female human embryonic stem cells is in a nonrandom pattern and prone to epigenetic alterations. Proc Nat Acad Sci USA. 105:4709–4714. 2008. View Article : Google Scholar : PubMed/NCBI

19 

Lengner CJ, Gimelbrant AA, Erwin JA, et al: Derivation of pre-X inactivation human embryonic stem cells under physiological oxygen concentrations. Cell. 141:872–883. 2010. View Article : Google Scholar : PubMed/NCBI

20 

Li T, Zhou CQ, Mai QY and Zhuang GL: Establishment of human embryonic stem cell line from gamete donors. Chin Med J (Engl). 118:116–122. 2005.

21 

Li T, Mai Q, Gao J and Zhou C: Cryopreservation of human embryonic stem cells with a new bulk vitrification method. Biol Reprod. 82:848–853. 2010. View Article : Google Scholar : PubMed/NCBI

22 

Ryan IP, Schriock ED and Taylor RN: Isolation, characterization, and comparison of human endometrial and endometriosis cells in vitro. J Clin Endocrinol Metab. 78:642–649. 1994.PubMed/NCBI

23 

Qin XY, Sone H, Kojima Y, et al: Individual variation of the genetic response to bisphenol a in human foreskin fibroblast cells derived from cryptorchidism and hypospadias patients. PLoS One. 7:e527562012. View Article : Google Scholar

24 

Fiorentino F1, Spizzichino L, Bono S, et al: PGD for reciprocal and Robertsonian translocations using array comparative genomic hybridization. Hum Reprod. 26:1925–1935. 2011. View Article : Google Scholar : PubMed/NCBI

25 

Brockdorff N, Ashworth A, Kay GF, et al: Conservation of position and exclusive expression of mouse Xist from the inactive X chromosome. Nature. 351:329–331. 1991. View Article : Google Scholar : PubMed/NCBI

26 

Brown CJ, Ballabio A, Rupert JL, Lafreniere RG, Grompe M, Tonlorenzi R and Willard HF: A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nature. 349:38–44. 1991. View Article : Google Scholar : PubMed/NCBI

27 

Penny GD, Kay GF, Sheardown SA, Rastan S and Brockdorff N: Requirement for Xist in X chromosome inactivation. Nature. 379:131–137. 1996. View Article : Google Scholar : PubMed/NCBI

28 

Heard E and Disteche CM: Dosage compensation in mammals: fine-tuning the expression of the X chromosome. Genes Dev. 20:1848–1867. 2006. View Article : Google Scholar : PubMed/NCBI

29 

Okamoto I, Otte AP, Allis CD, Reinberg D and Heard E: Epigenetic dynamics of imprinted X inactivation during early mouse development. Science. 303:644–649. 2004. View Article : Google Scholar

30 

Costanzi C and Pehrson JR: Histone macroH2A1 is concentrated in the inactive X chromosome of female mammals. Nature. 393:599–601. 1998. View Article : Google Scholar : PubMed/NCBI

31 

Chadwick BP and Willard HF: Cell cycle-dependent localization of macroH2A in chromatin of the inactive X chromosome. J Cell Biol. 157:1113–1123. 2002. View Article : Google Scholar : PubMed/NCBI

32 

Navarro P, Chambers I, Karwacki-Neisius V, Chureau C, Morey C, Rougeulle C and Avner P: Molecular coupling of Xist regulation and pluripotency. Science. 321:1693–1695. 2008. View Article : Google Scholar : PubMed/NCBI

33 

Kim K, Lerou P, Yabuuchi A, et al: Histocompatible embryonic stem cells by parthenogenesis. Science. 315:482–486. 2007. View Article : Google Scholar

34 

Taylor CJ, Bolton EM, Pocock S, Sharples LD, Pedersen RA and Bradley JA: Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet. 366:2019–2025. 2005. View Article : Google Scholar : PubMed/NCBI

35 

Jiang H, Sun B, Wang W, et al: Activation of paternally expressed imprinted genes in newly derived germline-competent mouse parthenogenetic embryonic stem cell lines. Cell Res. 17:792–803. 2007. View Article : Google Scholar : PubMed/NCBI

36 

Liu W, Yin Y, Jiang Y, et al: Genetic and epigenetic X-chromosome variations in a parthenogenetic human embryonic stem cell line. J Assist Reprod Genet. 28:303–313. 2011. View Article : Google Scholar :

37 

Allegrucci C and Young LE: Differences between human embryonic stem cell lines. Hum Reprod Update. 13:103–120. 2007. View Article : Google Scholar

38 

Liu W, Guo L, He W, Li Q and Sun X: Higher copy number variation and diverse X chromosome inactivation in parthenote-derived human embryonic stem cells. J Reprod Dev. 58:642–648. 2012. View Article : Google Scholar : PubMed/NCBI

39 

Ganesan S, Richardson AL, Wang ZC, et al: Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer. Cold Spring Harb Symp Quant Biol. 70:93–97. 2005. View Article : Google Scholar

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Qi Q, Ding C, Hong P, Yang G, Xie Y, Wang J, Huang S, He K and Zhou C: X chromosome inactivation in human parthenogenetic embryonic stem cells following prolonged passaging. Int J Mol Med 35: 569-578, 2015.
APA
Qi, Q., Ding, C., Hong, P., Yang, G., Xie, Y., Wang, J. ... Zhou, C. (2015). X chromosome inactivation in human parthenogenetic embryonic stem cells following prolonged passaging. International Journal of Molecular Medicine, 35, 569-578. https://doi.org/10.3892/ijmm.2014.2044
MLA
Qi, Q., Ding, C., Hong, P., Yang, G., Xie, Y., Wang, J., Huang, S., He, K., Zhou, C."X chromosome inactivation in human parthenogenetic embryonic stem cells following prolonged passaging". International Journal of Molecular Medicine 35.3 (2015): 569-578.
Chicago
Qi, Q., Ding, C., Hong, P., Yang, G., Xie, Y., Wang, J., Huang, S., He, K., Zhou, C."X chromosome inactivation in human parthenogenetic embryonic stem cells following prolonged passaging". International Journal of Molecular Medicine 35, no. 3 (2015): 569-578. https://doi.org/10.3892/ijmm.2014.2044
Copy and paste a formatted citation
x
Spandidos Publications style
Qi Q, Ding C, Hong P, Yang G, Xie Y, Wang J, Huang S, He K and Zhou C: X chromosome inactivation in human parthenogenetic embryonic stem cells following prolonged passaging. Int J Mol Med 35: 569-578, 2015.
APA
Qi, Q., Ding, C., Hong, P., Yang, G., Xie, Y., Wang, J. ... Zhou, C. (2015). X chromosome inactivation in human parthenogenetic embryonic stem cells following prolonged passaging. International Journal of Molecular Medicine, 35, 569-578. https://doi.org/10.3892/ijmm.2014.2044
MLA
Qi, Q., Ding, C., Hong, P., Yang, G., Xie, Y., Wang, J., Huang, S., He, K., Zhou, C."X chromosome inactivation in human parthenogenetic embryonic stem cells following prolonged passaging". International Journal of Molecular Medicine 35.3 (2015): 569-578.
Chicago
Qi, Q., Ding, C., Hong, P., Yang, G., Xie, Y., Wang, J., Huang, S., He, K., Zhou, C."X chromosome inactivation in human parthenogenetic embryonic stem cells following prolonged passaging". International Journal of Molecular Medicine 35, no. 3 (2015): 569-578. https://doi.org/10.3892/ijmm.2014.2044
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team